methyl 2-{[4-({[(5-methoxy-1H-indazol-3-yl)carbonyl]amino}methyl)piperidin-1-yl]methyl}-1,3-oxazole-4-carboxylate | 1452520-25-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: methyl 2-{[4-({[(5-methoxy-1H-indazol-3-yl)carbonyl]amino}methyl)piperidin-1-yl]methyl}-1,3-oxazole-4-carboxylate
• 英文别名: Methyl 2-{[4-({[(5-methoxy-1H-indazol-3-yl)carbonyl]amino}methyl) piperidin-1-yl]methyl}-1,3-oxazole-4-carboxylate；methyl 2-[[4-[[(5-methoxy-1H-indazole-3-carbonyl)amino]methyl]piperidin-1-yl]methyl]-1,3-oxazole-4-carboxylate
• CAS: 1452520-25-0
• 化学式: C₂₁H₂₅N₅O₅
• 分子量: 427.46
• InChiKey: VKJSYJBYBSYYPO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  31
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  123
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  methyl 2-{[4-({[(5-methoxy-1H-indazol-3-yl)carbonyl]amino}methyl)piperidin-1-yl]methyl}-1,3-oxazole-4-carboxylate 在 sodium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 以82%的产率得到2-{[4-({[(5-methoxy-1H-indazol-3-yl)carbonyl]amino}methyl)piperidin-1-yl]methyl}-1,3-oxazole-4-carboxylic acid
  参考文献：
  名称：

  Hit Optimization of 5-Substituted-N-(piperidin-4-ylmethyl)-1H-indazole-3-carboxamides: Potent Glycogen Synthase Kinase-3 (GSK-3) Inhibitors with in Vivo Activity in Model of Mood Disorders

  摘要：

  Novel treatments for bipolar disorder with improved efficacy and broader spectrum of activity are urgently needed. Glycogen synthase kinase 3 beta (GSK-3 beta) has been suggested to be a key player in the pathophysiology of bipolar disorder. A series of novel GSK-3 beta inhibitors having the common N-[(1-alkylpiperidin-4-yl)methyl]-1H-indazole-3-carboxamide scaffold were prepared taking advantage of an X-ray cocrystal structure of compound 5 with GSK-3 beta. We probed different substitutions at the indazole 5-position and at the piperidine-nitrogen to obtain potent ATP-competitive GSK-3 beta inhibitors with good cell activity. Among the compounds assessed in the in vivo PK experiments, 14i showed, after i.p. dosing, encouraging plasma PK profile and brain exposure, as well as efficacy in a mouse model of mania. Compound 14i was selected for further in vitro/in vivo pharmacological evaluation, in order to elucidate the use of ATP-competitive GSK-3 beta inhibitors as new tools in the development of new treatments for mood disorders

  DOI：

  10.1021/acs.jmedchem.5b01208
• 作为产物：
  描述：

  methyl 2-{[4-({[(5-methoxy-1H-indazol-3-yl)carbonyl]amino}methyl)piperidin-1-yl]methyl}-1,3-thiazole-4-carboxylate 、 (2-氯甲基)恶唑-甲酸甲酯 生成 methyl 2-{[4-({[(5-methoxy-1H-indazol-3-yl)carbonyl]amino}methyl)piperidin-1-yl]methyl}-1,3-oxazole-4-carboxylate
  参考文献：
  名称：

  NEW USE OF 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS

  摘要：

  1H-吲唑-3-羧酰胺类化合物作为糖原合成酶激酶3β抑制剂。本发明涉及1H-吲唑-3-羧酰胺类化合物，用于作为糖原合成酶激酶3β（GSK-33）抑制剂，并用于治疗GSK-3p相关疾病，例如（i）胰岛素抵抗性疾病；（ii）神经退行性疾病；（iii）情绪障碍；（iv）精神分裂症；（v）癌症性疾病；（vi）炎症；（vii）物质滥用障碍；和（viii）癫痫病。

  公开号：

  US20140378455A1

文献信息

• [EN] USE OF 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS<br/>[FR] UTILISATION DES COMPOSÉS 1H-INDAZOLE-3-CARBOXAMIDE EN TANT QU'INHIBITEURS DE LA GLYCOGÈNE SYNTHASE KINASE 3 BÊTA
  申请人：ACRAF

  公开号：WO2013124169A1

  公开（公告）日：2013-08-29

  1 H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors. The present invention relates to the 1 H-indazole-3-carboxamide compounds for use as glycogen synthase kinase 3 beta (GSK-33) inhibitors and to their use in the treatment of GSK-3p-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; and (viii) epilepsies.

  1- H-吲唑-3-羧酰胺化合物作为糖原合成酶激酶3β抑制剂。本发明涉及用于作为糖原合成酶激酶3β（GSK-33）抑制剂的1- H-吲唑-3-羧酰胺化合物，以及它们在治疗GSK-3β相关疾病中的应用，例如（i）胰岛素抵抗性疾病；（ii）神经退行性疾病；（iii）情绪障碍；（iv）精神分裂症性障碍；（v）癌症性障碍；（vi）炎症；（vii）物质滥用障碍；以及（viii）癫痫。
• Use of 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
  申请人：AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A.

  公开号：US09163013B2

  公开（公告）日：2015-10-20

  1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors. The present invention relates to the 1H-indazole-3-carboxamide compounds for use as glycogen synthase kinase 3 beta (GSK-3β) inhibitors and to their use in the treatment of GSK-3β-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; and (viii) epilepsies.

  1H-吲唑-3-羧酰胺类化合物作为糖原合酶激酶3β抑制剂。本发明涉及1H-吲唑-3-羧酰胺类化合物，用作糖原合酶激酶3β（GSK-3β）抑制剂，并用于治疗GSK-3β相关疾病，例如（i）胰岛素抵抗性疾病；（ii）神经退行性疾病；（iii）情绪障碍；（iv）精神分裂症；（v）癌症性疾病；（vi）炎症，（vii）物质滥用障碍；和（viii）癫痫病。
• USE OF 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS
  申请人：AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO - A.C.R.A.F. - S.p.A.

  公开号：EP2817301A1

  公开（公告）日：2014-12-31
• US9163013B2
  申请人：——

  公开号：US9163013B2

  公开（公告）日：2015-10-20
• US9700551B2
  申请人：——

  公开号：US9700551B2

  公开（公告）日：2017-07-11